| Pathogenic lysosomal depletion in Parkinson's disease B Dehay, J Bové, N Rodríguez-Muela, C Perier, A Recasens, P Boya, ... Journal of Neuroscience 30 (37), 12535-12544, 2010 | 921 | 2010 |
| Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys A Recasens, B Dehay, J Bové, I Carballo‐Carbajal, S Dovero, ... Annals of neurology 75 (3), 351-362, 2014 | 689 | 2014 |
| Targeting cancer cell dormancy A Recasens, L Munoz Trends in pharmacological sciences 40 (2), 128-141, 2019 | 262 | 2019 |
| Alpha-synuclein spreading in Parkinson’s disease A Recasens, B Dehay Frontiers in neuroanatomy 8, 159, 2014 | 240 | 2014 |
| Selective α-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson’s disease D Alarcón-Arís, A Recasens, M Galofré, I Carballo-Carbajal, N Zacchi, ... Molecular Therapy 26 (2), 550-567, 2018 | 123 | 2018 |
| Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency D Ramonet, C Perier, A Recasens, B Dehay, J Bove, V Costa, L Scorrano, ... Cell Death & Differentiation 20 (1), 77-85, 2013 | 99 | 2013 |
| BAX channel activity mediates lysosomal disruption linked to Parkinson disease J Bové, M Martínez-Vicente, B Dehay, C Perier, A Recasens, A Bombrun, ... Autophagy 10 (5), 889-900, 2014 | 89 | 2014 |
| In vivo models of alpha-synuclein transmission and propagation A Recasens, A Ulusoy, PJ Kahle, DA Di Monte, B Dehay Cell and tissue research 373, 183-193, 2018 | 70 | 2018 |
| Role of microRNAs in the regulation of α-synuclein expression: a systematic review A Recasens, C Perier, CM Sue Frontiers in molecular neuroscience 9, 128, 2016 | 44 | 2016 |
| Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates M Bourdenx, A Nioche, S Dovero, ML Arotcarena, S Camus, G Porras, ... Science advances 6 (20), eaaz9165, 2020 | 38 | 2020 |
| Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells A Recasens, SJ Humphrey, M Ellis, M Hoque, RH Abbassi, B Chen, ... Cell death discovery 7 (1), 81, 2021 | 29 | 2021 |
| Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients A Recasens, I Carballo-Carbajal, A Parent, J Bové, E Gelpi, E Tolosa, ... Acta neuropathologica communications 6, 1-9, 2018 | 28 | 2018 |
| DYRK1A negatively regulates CDK5-SOX2 pathway and self-renewal of glioblastoma stem cells B Chen, D McCuaig-Walton, S Tan, AP Montgomery, BW Day, M Kassiou, ... International journal of molecular sciences 22 (8), 4011, 2021 | 16 | 2021 |
| Lower tubulin expression in glioblastoma stem cells attenuates efficacy of microtubule-targeting agents RH Abbassi, A Recasens, DC Indurthi, TG Johns, BW Stringer, BW Day, ... ACS Pharmacology & Translational Science 2 (6), 402-413, 2019 | 16 | 2019 |
| MK2 inhibition induces p53-dependent senescence in glioblastoma cells AF Phoa, A Recasens, FMS Gurgis, TA Betts, SV Menezes, D Chau, ... Cancers 12 (3), 654, 2020 | 4 | 2020 |
| MerTK activity is not necessary for the proliferation of glioblastoma stem cells M Hoque, SW Wong, A Recasens, R Abbassi, N Nguyen, D Zhang, ... Biochemical Pharmacology 186, 114437, 2021 | 2 | 2021 |
| Identification of distinct pathological signatures induced by patient-derived-synuclein structures in nonhuman primates MT Herrero Ezquerro, M Bourdenx, A Nioche, S Dovero, ML Arotcarena, ... Asociación Estadounidense para el Avance de la Ciencia, 2020 | | 2020 |
| Abstract A064: MK2 inhibition stabilizes wild-type and mutated p53 in glioblastoma cells and leads to different cellular responses AF Phoa, A Recasens, L Munoz Molecular Cancer Therapeutics 18 (12_Supplement), A064-A064, 2019 | | 2019 |
| Bidirectional gut-to-brain and brain-to-gut propagation of alpha-synuclein pathology in non-human primates ML Arotcarena, S Dovero, A Prigent, M Bourdenx, P Aubert, I Trigo, ... MOVEMENT DISORDERS 33, S773-S773, 2018 | | 2018 |
| Variable selection using machine-learning to identify new signatures of patient-derived aggregated alpha-synuclein-induced neurodegeneration in non-human primates M Bourdenx, A Nioche, S Dovero, ML Arotcarena, S Camus, G Porras, ... MOVEMENT DISORDERS 33, S786-S787, 2018 | | 2018 |
